Drug Trial Radar · NCT04481607
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Planned (sponsor's estimate)
Start
Aug 24, 2020
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.
Conditions
- Advanced Solid Tumor or Hematologic Tumor
Interventions
TQB3454Drug
TQB3454 tablets is a small molecule oral drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Baseline up to 28 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The Affiliated Hosptial of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Tianjing Medical University Cancer Institute&Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hosptial Zhejiang University School of Medical
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.